Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Ladostigil (1-10 µM) demonstrates neuroprotective effects by preventing the decline in mitochondrial membrane potential (ψ), reducing apoptotic cascades, and inhibiting the production of reactive oxygen species (ROS) induced by OS insults.[6]
Ladostigil (1-10 µM) exhibits notable neuroprotective effects in human neuroblastoma SK-N-SH cells. These effects involve the inhibition of caspase-3 activation, upregulation of Bcl-2 expression, and downregulation of Bad and Bax gene and protein expression.[6]

Ladostigil (17 mg/kg; p.o. daily for 6 weeks) eliminates hyperanxiety and depressive-like behavior in adulthood in rats exposed to prenatal stress, spanning from puberty to the adult stage. This effect is demonstrated in both the elevated plus maze (EPM) and forced swim tests (FST).[8]
Ladostigil (50 μmol/kg; single p.o.) restores the loss of episodic memory in the object recognition test in rats.[7]